Hydroxychloroquine sulfate/Sirolimus

硫酸羟氯喹/西罗莫司

Report date: 2026/03/04 20:01:44

Base Information

Drug NameHydroxychloroquine sulfate/Sirolimus
Drug Alias Name西罗莫司/硫酸羟氯喹Hydroxychloroquine sulfate + SirolimusSirolimus/Hydroxychloroquine hydrosulfate西罗莫司+硫酸羟氯喹硫酸羟氯喹+西罗莫司 +[10] 
ClassificationSmall moleculesSmall molecules > Molecular Glue
Mechanisms of ActionMammalian target of Rapamycin (mTORC1) inhibitorsmTOR Complex 2 inhibitorsApoptosis stimulants +[5] 
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsYes Hydroxychloroquine sulfateSirolimus
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJohnpro Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Huibaoyuan Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A